Evommune, Inc. (EVMN)
NYSE: EVMN · Pharmaceutical Preparations · Palo Alto, CA · filing with the SEC since 2025
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 |
| Report filed | Mar 5, 2026 | · |
| Revenue | 13,000 | 7,000 |
| Research and development | 74,042 | 64,244 |
| General and administrative | 20,029 | 12,769 |
| Total operating expenses | 94,071 | 77,013 |
| Operating income | -81,071 | -70,013 |
| Interest and investment income | 3,323 | 3,242 |
| Other income (expense), net | 12,201 | 3,205 |
| Income before income taxes | -68,870 | -68,308 |
| Income tax expense | 0 | 0 |
| Net income including non-controlling interests | -68,870 | -66,808 |
| Net income | -68,870 | -66,808 |
| Net income to common shareholders | -68,870 | -68,308 |
| Earnings per share, basic | -11.22 | -45.29 |
| Earnings per share, diluted | -11.22 | -45.29 |
| Weighted average shares, basic | 6,136,636 | 1,508,284 |
| Weighted average shares, diluted | 6,136,636 | 1,508,284 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding